Cargando…

Heparan sulphate synthetic and editing enzymes in ovarian cancer

Several angiogenic growth factors including fibroblast growth factors 1 and 2 (FGF1 and FGF2) depend on heparan sulphate (HS) for biological activity. We previously showed that all cellular elements in ovarian tumour tissue synthesised HS but biologically active HS (i.e. HS capable of binding FGF2 a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Backen, A C, Cole, C L, Lau, S C, Clamp, A R, McVey, R, Gallagher, J T, Jayson, G C
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2007
Materias:	Molecular Diagnostics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2359940/ https://www.ncbi.nlm.nih.gov/pubmed/17437011 http://dx.doi.org/10.1038/sj.bjc.6603747

Ejemplares similares

Profiling Heparan Sulfate Proteoglycans in Ovarian Carcinoma
por: Clamp, Andrew R., et al.
Publicado: (2005)

Issues on fit-for-purpose validation of a panel of ELISAs for application as biomarkers in clinical trials of anti-Angiogenic drugs
por: Brookes, K, et al.
Publicado: (2010)

Systematic analysis of circulating soluble angiogenesis-associated proteins in ICON7 identifies Tie2 as a biomarker of vascular progression on bevacizumab
por: Zhou, Cong, et al.
Publicado: (2016)

DCE-MRI biomarkers of tumour heterogeneity predict CRC liver metastasis shrinkage following bevacizumab and FOLFOX-6
por: O'Connor, J P B, et al.
Publicado: (2011)

A pilot study to explore circulating tumour cells in pancreatic cancer as a novel biomarker
por: Khoja, L, et al.
Publicado: (2012)

Prognostic role of CIP2A expression in serous ovarian cancer
por: Böckelman, C, et al.
Publicado: (2011)

Androgen-related expression of G-proteins in ovarian cancer
por: Sheach, L A, et al.
Publicado: (2009)

A putative OTU domain-containing protein 1 deubiquitinating enzyme is differentially expressed in thyroid cancer and identifies less-aggressive tumours
por: Carneiro, A P, et al.
Publicado: (2014)

High mesothelin correlates with chemoresistance and poor survival in epithelial ovarian carcinoma
por: Cheng, W-F, et al.
Publicado: (2009)

Ovarian cancer stem-like side-population cells are tumourigenic and chemoresistant
por: Hu, L, et al.
Publicado: (2010)

Granulocyte colony-stimulating factor receptor signalling via Janus kinase 2/signal transducer and activator of transcription 3 in ovarian cancer
por: Kumar, J, et al.
Publicado: (2014)

Gene expression profiling of primary cultures of ovarian epithelial cells identifies novel molecular classifiers of ovarian cancer
por: Le Page, C, et al.
Publicado: (2006)

A distinct molecular profile associated with mucinous epithelial ovarian cancer
por: Heinzelmann-Schwarz, V A, et al.
Publicado: (2006)

Mammaglobin B (SCGB2A1) is a novel tumour antigen highly differentially expressed in all major histological types of ovarian cancer: implications for ovarian cancer immunotherapy
por: Bellone, S, et al.
Publicado: (2013)

In ovarian cancer the prognostic influence of HER2/neu is not dependent on the CXCR4/SDF-1 signalling pathway
por: Pils, D, et al.
Publicado: (2007)

Matrix heparan sulphate, but not endothelial cell surface heparan sulphate, is degraded by highly metastatic mouse lymphoma cells.
por: Hennes, R., et al.
Publicado: (1988)

hTERT phosphorylation by PKC is essential for telomerase holoprotein integrity and enzyme activity in head neck cancer cells
por: Chang, J T, et al.
Publicado: (2006)

Targeting EGFR and PI3K pathways in ovarian cancer
por: Glaysher, S, et al.
Publicado: (2013)

Role of lymphangiogenesis in epithelial ovarian cancer
por: Sundar, S S, et al.
Publicado: (2006)

The glycosphingolipid P(1) is an ovarian cancer-associated carbohydrate antigen involved in migration
por: Jacob, F, et al.
Publicado: (2014)

Targeting pancreatic and ovarian carcinomas using the auristatin-based anti-CD70 antibody–drug conjugate SGN-75
por: Ryan, M C, et al.
Publicado: (2010)

Ovarian carcinoma diagnosis: the clinical impact of 15 years of change
por: Kommoss, Stefan, et al.
Publicado: (2016)

Enhanced expression of peroxisome proliferator-activated receptor gamma in epithelial ovarian carcinoma
por: Zhang, G Y, et al.
Publicado: (2005)

Circulating biomarkers for detection of ovarian cancer and predicting cancer outcomes
por: Shapira, I, et al.
Publicado: (2014)

An immunohistochemical perspective of PPARβ and one of its putative targets PDK1 in normal ovaries, benign and malignant ovarian tumours
por: Ahmed, N, et al.
Publicado: (2008)

c-FOS suppresses ovarian cancer progression by changing adhesion
por: Oliveira-Ferrer, L, et al.
Publicado: (2014)

Overexpression of LASP-1 mediates migration and proliferation of human ovarian cancer cells and influences zyxin localisation
por: Grunewald, T G P, et al.
Publicado: (2007)

Δ133p53 is an independent prognostic marker in p53 mutant advanced serous ovarian cancer
por: Hofstetter, G, et al.
Publicado: (2011)

The E3 ubiquitin ligase EDD is an adverse prognostic factor for serous epithelial ovarian cancer and modulates cisplatin resistance in vitro
por: O'Brien, P M, et al.
Publicado: (2008)

Expression of steroid receptor coactivator 3 in ovarian epithelial cancer is a poor prognostic factor and a marker for platinum resistance
por: Palmieri, C, et al.
Publicado: (2013)

Downregulation of cell surface CA125/MUC16 induces epithelial-to-mesenchymal transition and restores EGFR signalling in NIH:OVCAR3 ovarian carcinoma cells
por: Comamala, M, et al.
Publicado: (2011)

Identification of candidate circulating cisplatin-resistant biomarkers from epithelial ovarian carcinoma cell secretomes
por: Teng, P-N, et al.
Publicado: (2014)

Heparin, Heparan Sulphate and the TGF-β Cytokine Superfamily
por: Rider, Chris C., et al.
Publicado: (2017)

Expression of lysophosphatidic acid acyltransferase beta (LPAAT-β) in ovarian carcinoma: correlation with tumour grading and prognosis
por: Niesporek, S, et al.
Publicado: (2005)

Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts
por: Huhtinen, K, et al.
Publicado: (2009)

Cross talk of signals between EGFR and IL-6R through JAK2/STAT3 mediate epithelial–mesenchymal transition in ovarian carcinomas
por: Colomiere, M, et al.
Publicado: (2009)

C-Fos expression is a molecular predictor of progression and survival in epithelial ovarian carcinoma
por: Mahner, S, et al.
Publicado: (2008)

Expression of a disintegrin and metalloprotease (ADAM and ADAMTS) enzymes in human non-small-cell lung carcinomas (NSCLC)
por: Rocks, N, et al.
Publicado: (2006)

Validation of Recombinant Heparan Sulphate Reagents for CNS Repair
por: Lindsay, Susan L., et al.
Publicado: (2023)

Autoantibodies to MUC1 glycopeptides cannot be used as a screening assay for early detection of breast, ovarian, lung or pancreatic cancer
por: Burford, B, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_31nkk493d1do8t80qun58dk3l4